United Kingdom

People: Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

23 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Andrews, Sean 

Mr. Sean Andrews is Vice President, Investor Relations of the Company. Mr. Andrews has served as Sienna's Senior Director, Investor Relations, since May 2017. During that time, he was instrumental to Sienna's successful initial public offering (IPO) and transition to being a public company, and was a strong business partner to both the CEO and CFO regarding the Company's IR and corporate strategy, including messaging, investor targeting, corporate financing, pipeline evaluation and business development. Prior to joining Sienna, from January 2016 to April 2017, Mr. Andrews served as Senior Director of Investor Relations at Novan, Inc., where he was integral to its successful IPO and transition to being a public company and chaired its disclosure committee. From June 2013 through December 2015, Mr. Andrews was Managing Partner of Credible Strategic Advisors, where he provided investor relations and corporate strategy consulting services and assisted sell-side equity research teams with company and asset valuations. Previously, Mr. Andrews served in roles of increasing responsibility at Medicis Pharmaceutical Corp., most recently as Director, Investor Relations, from January 2008 until it was acquired by Valeant in December 2012. Mr. Andrews is a United States Air Force veteran, and holds undergraduate degrees in aircraft systems maintenance technology and instructor of technology and military science. He is a member of the National Investor Relations Institute and the Public Relations Society of America.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --